Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Chidamide + Gemcitabine + S1 in Advanced Pancreatic Cancer
NCT06584227Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and tucidinostat in pancreatic cancer (PC). Primary endpoint: Progression-Free Survival at 24 months. Started Sep 2024; status: recruiting.
02
Drugs
adebrelimabtucidinostat
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06584227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584227.